Quote | Candel Therapeutics Inc. (NASDAQ:CADL)
Last: | $8.90 |
---|---|
Change Percent: | -2.78% |
Open: | $8.86 |
Close: | $8.90 |
High: | $9.27 |
Low: | $8.65 |
Volume: | 625,443 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Candel Therapeutics Inc. (NASDAQ:CADL)
2024-05-30 08:50:10 ET More on Candel Therapeutics Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer Candel Therapeutics GAAP EPS of -$0.28 Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment ...
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approved CAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poste...
Message Board Posts | Candel Therapeutics Inc. (NASDAQ:CADL)
Subject | By | Source | When |
---|---|---|---|
$CADL here we go bulls news is here | MiamiGent | investorshub | 04/25/2023 7:34:02 PM |
where is the squeeze? | subslover | investorshub | 04/25/2023 7:07:26 AM |
$CADL got some short data | MiamiGent | investorshub | 04/23/2023 9:01:49 AM |
where is the squeeze? | subslover | investorshub | 04/17/2023 10:33:11 AM |
$CADL Looks pretty positive | axelvento | investorshub | 04/04/2023 11:28:03 AM |
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approved CAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poste...
2024-05-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immun...